Rapamycin-insensitive companion of mechanistic target of rapamycin (RICTOR)

Rapamycin-insensitive companion of mechanistic target of rapamycin (RICTOR) is a defining component and adaptor protein of the mechanistic target of rapamycin complex 2 (mTORC2). RICTOR was first identified in 2004 as a novel binding partner of mTOR that forms a distinct complex separate from mTORC1, which contains raptor instead of RICTOR[1]. RICTOR shares homology with pianissimo from Dictyostelium discoideum, STE20p from Schizosaccharomyces pombe, and AVO3p from Saccharomyces cerevisiae[1]. The protein serves as a structural component that determines the rapamycin-insensitivity of mTORC2, as the rapamycin-FKBP12 complex does not directly bind or inhibit mTORC2 in acute treatment[2]. The RICTOR-containing mTORC2 complex includes mTOR, mLST8 (also known as GβL), mSin1, Protor1/2, and DEPTOR, but notably does not contain raptor[2]. This complex plays a critical role as a downstream effector of insulin and phosphoinositide 3-kinase signaling pathways[2][3]. The mSin1 subunit contains a phosphoinositide-binding PH domain that is essential for insulin-dependent regulation of mTORC2 activity, with autoinhibition being relieved upon binding to PI3K-generated PIP3 at the plasma membrane[2][3]. mTORC2 directly phosphorylates AKT at serine 473 in the hydrophobic motif, which is essential for full AKT activation and facilitates threonine 308 phosphorylation by PDK1[1][4]. Through AKT activation, mTORC2 regulates multiple downstream pathways including FOXO-dependent processes, cell survival, proliferation, and metabolism[4]. The complex also modulates protein kinase C alpha phosphorylation and actin cytoskeleton organization[1]. Genetic studies have demonstrated that RICTOR is essential for insulin signaling and glucose homeostasis. Liver-specific RICTOR knockout mice exhibit severe insulin resistance and glucose intolerance, as do mice lacking RICTOR in muscle or adipose tissue[2]. These findings establish mTORC2 as a critical mediator of metabolic regulation. In cancer biology, constitutive activation of mTOR signaling pathways, including mTORC2, has been implicated in tumorigenesis. RICTOR expression and mTORC2 activity are frequently elevated in various human malignancies[3]. The complex plays roles in cancer cell survival, proliferation, and migration, making it a potential therapeutic target. An important regulatory feature is the negative feedback loop between mTORC1 and mTORC2. mTORC1 activation leads to phosphorylation of substrates like S6K1, which suppresses mTORC2 activation through degradation of insulin receptor substrate 1[2][3]. This crosstalk has significant implications for pharmacological targeting strategies. While acute rapamycin treatment specifically inhibits mTORC1, prolonged rapamycin exposure can inhibit mTORC2 signaling in vivo, likely by preventing rapamycin-bound mTOR from incorporating into newly formed mTORC2 complexes[2]. This explains the paradoxical observation that chronic rapamycin treatment causes insulin resistance despite mTORC1 hyperactivation being associated with insulin resistance[2]. RICTOR also plays important roles in aging and cardiac health. Cardiac-specific overexpression of RICTOR promotes autophagic flux, preserves cardiac function during aging, and extends lifespan in Drosophila models[4]. This suggests that manipulation of mTORC2 signaling in the heart has systemic effects on longevity control.

Other names

RictorRICTORrapamycin-insensitive companion of TORrapamycin-insensitive companion of mTORAVO3 (yeast homolog)pianissimo homolog (Drosophila homolog)

Structural component of mechanistic target of rapamycin complex 2 that enables AKT phosphorylation at serine 473. Mediates insulin and phosphoinositide 3-kinase signaling pathway activation. Regulates protein kinase C alpha phosphorylation and actin cytoskeleton organization.